{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-009050","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.895638+00:00","generated_at":"2026-06-18T21:46:10.523695+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Bristol-Myers reports no CVR payment due for Abraxane 2022 net sales of $909M","bullets":["2022 Abraxane net sales of $908,974,933 triggered no payment under Celgene CVR agreement.","Company notified trustee on Feb 23, 2023; no Net Sales Payment due per CVR terms.","CVR relates to Celgene acquisition from Nov 2019; future payments may be disclosed on BMS website."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-009050","json":"https://secwatch.observer/filing/0001140361-23-009050.json","markdown":"https://secwatch.observer/filing/0001140361-23-009050.md","text":"https://secwatch.observer/filing/0001140361-23-009050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000114036123009050/0001140361-23-009050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000114036123009050/brhc10048710_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:46:10.523695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}